Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q3 FY21 results · Oct–Dec 2020

Jubilant Pharmova reported revenue from operations of ₹1,771.34 crore (down 23.5% from Q3 FY20) and net profit of ₹309.83 crore (up 52.3% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY21	Q3 FY20	YoY	Q2 FY21	QoQ
Revenue from operations	1,771.34	2,315.21	−23.5%	2,374.89	−25.4%
Other income	3.59	6.03	−40.5%	7.28	−50.7%
Total income	1,774.93	2,321.24	−23.5%	2,382.17	−25.5%
Profit before share of associates & JVs and tax	343.15	293.32	+17.0%	313.67	+9.4%
Share of profit/(loss) of associates & JVs	(3.10)	0.00		0.00
Net profit for the period	309.83	203.38	+52.3%	224.12	+38.2%
Attributable to shareholders of the company	309.93	203.38	+52.4%	224.03	+38.3%
EPS, basic (₹)	19.46	12.77	+52.4%	14.06	+38.4%
Net margin (%)	17.5	8.8		9.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY21	Q3 FY20	YoY	Q2 FY21	QoQ
Revenue from operations	828.94	801.18	+3.5%	760.75	+9.0%
Other income	12.21	5.52	+121.2%	12.89	−5.3%
Total income	841.15	806.70	+4.3%	773.64	+8.7%
Profit before tax	80.99	34.96	+131.7%	75.23	+7.7%
Net profit for the period	64.65	34.63	+86.7%	62.63	+3.2%
EPS, basic (₹)	4.06	2.17	+87.1%	3.93	+3.3%
Net margin (%)	7.8	4.3		8.2

Consolidated

Filed with BSE: 06 Feb 2021, 08:48 IST
Board meeting: 05 Feb 2021
Period: 01 Oct 2020 to 31 Dec 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 06 Feb 2021, 08:48 IST
Board meeting: 05 Feb 2021
Period: 01 Oct 2020 to 31 Dec 2020
Review status: Unaudited
Source: XBRL filing on BSE